ReviewFrontiers in pharmacology2022
Update on Treatment of Infantile Hemangiomas: What's New in the Last Five Years?
Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Population Pharmacokinetics of Topical Timolol Maleate Gel in Healthy Volunteers and Infants With Superficial Infantile Hemangioma.CPT: pharmacometrics & systems pharmacology · 2026Article
- Review
- Thermoresponsive Hydroxybutyl Chitosan-Assisted Carteolol Delivery with Pulsed Dye Laser for Superficial Infantile Hemangiomas: An Exploratory Randomized Study.Clinical, cosmetic and investigational dermatology · 2026Article
- Unveiling Infantile Hemangiomas: A Comprehensive Study of Patterns, Presentations, and Complications.Dermatology practical & conceptual · 2025Article
- The Regression Heterogeneity Pattern of Infantile Haemangiomas after Treatment with Propranolol: A Multicentre Retrospective Study.Acta dermato-venereologica · 2025Article
- Image Sensor-Driven 3D Modeling of Complex Biological Surfaces for Preoperative Planning of Hemangioma Treatment.Sensors (Basel, Switzerland) · 2025Article
- Knowledge, attitudes, and practices on hemangioma among parents of infantile hemangioma patients in South China.Scientific reports · 2025Article
- Nanotechnology in Infantile Hemangioma Management.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025Article
- Efficacy and safety of propranolol tablets vs. oral solution in neonates with severe infantile hemangiomas: a retrospective study in China.Scientific reports · 2025Article
- Efficacy and safety assessment of propranolol tablets vs. oral solution for infantile hemangioma: a retrospective study in China.Frontiers in pediatrics · 2025Article
- Assessing Response Rates and Sleep Disorder Prevalence: Insights from a Propranolol Treatment Study for Infantile Haemangiomas.Children (Basel, Switzerland) · 2024Article
- Current and Future Treatment Options for Cerebral Cavernous Malformations.Stroke (Hoboken, N.J.) · 2024Review
- Clinical characteristics of infantile haemangioma in twins: a retrospective study.BMC pediatrics · 2024Article
- Postnatal treatment and evolution patterns of giant fetal hepatic hemangioma: a case series of 29 patients.BMC pediatrics · 2024Article
- Historical and contemporary management of infantile hemangiomas: a single-center experience.Frontiers in pharmacology · 2024Article
- Case report: Deterioration of infantile hemangioma related to oral or nebulized administration of β2-AR agonist: Three cases reports.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among benign vascular tumors of infancy, hemangiomas are the commonest, affecting approximately 5-10% of one-year-old children. They are derived from a benign proliferation of vascular endothelial cells (VECs) in the mesoderm and may arise anywhere on the body around 1-2 weeks after birth. Infantile hemangiomas (IHs) are characterized by an early proliferative phase in the first year followed by a spontaneous progressive regression within the following 5 years or longer. IH prevalence is estimated to be 5%-10% in one-year-old children and commonly affects female, Caucasian and low-birth weight infants. Although most of them spontaneously regress, approximately 10% requires treatment to prevent complications due to the site of occurrence such as bleeding, ulceration, cosmetically disfigurement, functional impairment, or life-threatening complications. For over 30 years, steroids have represented the first-line treatment for IHs, but recently topical or systemic β-blockers are increasingly being used and recognized as effective and safe. A search for "Cutaneous infantile hemangioma" [All Fields] AND "Treatment" [All Fields] was performed by using PubMed and EMBASE databases. Treatment of IHs with labeled drugs, such as oral propranolol, but also with off-label drugs, such as topical β-blockers, including topical timolol and carteolol, steroids, itraconazole or sirolimus, with a focus on formulations types and adverse events were described in our review. We also discussed the benefits of pulsed dye laser and the treatment of IHs with involvement of central nervous system, namely the PHACE and LUMBAR syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.